-
1.发明申请HUMAN BINDING MOLECULES CAPABLE OF NEUTRALIZING INFLUENZA VIRUS H5N1 AND USES THEREOF 有权能够中和流感病毒H5N1的人结合分子及其用途公开(公告)号：US20160024188A1
公开(公告)日：2016-01-28
申请号：US14817707
申请日：2015-08-04
申请人： CRUCELL HOLLAND B.V.
IPC分类号： C07K16/10 , G01N33/569
CPC分类号： C07K16/1018 , A61K2039/505 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C12N2760/00011 , C12N2760/00061 , C12N2760/16011 , C12N2760/16061 , C12N2760/16111 , G01N33/56983 , G01N2333/11 , G01N2469/10
摘要： Described are binding molecules such as human monoclonal antibodies that bind to influenza virus H5N1 and have neutralizing activity against influenza virus H5N1. Also described are polynucleotides encoding the antibodies, and compositions comprising the antibodies and methods of identifying or producing the antibodies. The antibodies can be used in the diagnosis, prophylaxis, and/or treatment of an influenza virus H5N1 infection. In certain embodiments, the antibodies provide cross-subtype protection in vivo, such that infections with H5, H2, H6, H9, and H1-based influenza subtypes can be prevented and/or treated.
摘要翻译： 描述了结合分子，例如结合流感病毒H5N1的人单克隆抗体，并具有针对流感病毒H5N1的中和活性。 还描述了编码抗体的多核苷酸，以及包含抗体的组合物以及鉴定或产生抗体的方法。 抗体可用于诊断，预防和/或治疗流感病毒H5N1感染。 在某些实施方案中，抗体在体内提供跨亚型保护，使得可以预防和/或治疗H5，H2，H6，H9和H1基于流感亚型的感染。
-
公开(公告)号：US20140302091A1
公开(公告)日：2014-10-09
申请号：US13300217
申请日：2011-11-18
CPC分类号： A61K39/12 , A61K47/26 , A61K47/36 , A61K47/42 , A61K2039/5254 , A61K2039/55555 , A61K2039/70 , C08G2650/58 , C08L71/02 , C08L2203/02 , C12N7/00 , C12N2710/10051 , C12N2710/10061 , C12N2710/24151 , C12N2710/24161 , C12N2760/16051 , C12N2760/16061 , C12N2760/18411 , C12N2770/24134 , C12N2770/24151 , C12N2770/24161 , C12N2770/36151 , C12N2770/36161 , Y02A50/386 , Y02A50/388 , Y02A50/39 , Y02A50/394 , Y02A50/396
摘要： Embodiments herein relate to compositions of and methods for live viruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated viruses and compositions to reduce inactivation and/or degradation of the live, attenuated virus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated virus composition may include at least one carbohydrate, at least one protein and at least one high molecular weight surfactants for reducing inactivation and/or degradation of the live, attenuated virus.
摘要翻译： 本文的实施方案涉及活病毒的组合物和方法。 在某些实施方案中，活的减毒病毒组合物包括但不限于一种或多种活的，减毒的病毒和组合物，以减少活的，减毒的病毒的失活和/或降解。 在其它实施方案中，活的减毒病毒组合物可以是疫苗组合物。 在其它组合物中，活的减毒病毒组合物可包括至少一种碳水化合物，至少一种蛋白质和至少一种用于减少活的，减毒病毒的失活和/或降解的高分子量表面活性剂。
-
公开(公告)号：US20100129400A1
公开(公告)日：2010-05-27
申请号：US12686200
申请日：2010-01-12
申请人： Craig Cameron , Jamie Arnold , Avery August
发明人： Craig Cameron , Jamie Arnold , Avery August
IPC分类号： A61K39/21 , A61K39/12 , A61K39/145 , A61K39/13 , A61P37/00 , A61P31/12 , A61P31/18 , A61P31/16
CPC分类号： A61K39/13 , A61K39/12 , A61K39/145 , A61K39/21 , A61K2039/5254 , A61K2039/54 , A61K2039/545 , C12N7/00 , C12N9/1241 , C12N2740/16034 , C12N2740/16061 , C12N2760/16034 , C12N2760/16061 , C12N2770/32634 , C12N2770/32661 , Y02A50/466
摘要： The invention encompasses compositions and methods relating to viral polymerases having one or more substitutions of different amino acids at conserved regions of the polymerase yields enzymes with varying rates and fidelity of replication. A universally applicable, polymerase-mechanism-based strategy for production of attenuated viruses and anti-viral vaccines is disclosed. Attenuated viruses serve as vaccines and were shown to provide protection against poliovirus challenge in vivo.
摘要翻译： 本发明包括与在聚合酶的保守区域具有一个或多个不同氨基酸取代的病毒聚合酶有关的组合物和方法产生具有不同的复制率和保真度的酶。 公开了用于生产减毒病毒和抗病毒疫苗的普遍适用的基于聚合酶机制的策略。 减毒的病毒作为疫苗，并被证明可以在体内提供抗脊髓灰质炎病毒攻击的保护。
-
公开(公告)号：US20240228981A1
公开(公告)日：2024-07-11
申请号：US18512196
申请日：2023-11-17
发明人： Eckard Wimmer , Steve Skiena , Steffen Mueller , Bruce Futcher , Dimitris Papamichail , John Robert Coleman , Jeronimo Cello
IPC分类号： C12N7/00 , A61K39/00 , A61K39/12 , A61K39/13 , A61K39/145 , C07K14/005
CPC分类号： C12N7/00 , A61K39/12 , A61K39/13 , A61K39/145 , C07K14/005 , A61K2039/5254 , C12N2720/12361 , C12N2740/15061 , C12N2760/16061 , C12N2760/16121 , C12N2760/16134 , C12N2760/16162 , C12N2770/20061 , C12N2770/24161 , C12N2770/32061 , C12N2770/32621 , C12N2770/32634 , C12N2770/32661 , C12N2770/32662 , C12N2770/32671 , C12N2770/32721 , C12N2770/32761 , C12N2770/32762 , Y02A50/30
摘要： This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the instant attenuated virus. Further, this invention further provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of a vaccine composition comprising the instant attenuated virus.
-
公开(公告)号：US20230159886A1
公开(公告)日：2023-05-25
申请号：US17954128
申请日：2022-09-27
申请人： Genentech, Inc.
发明人： Masaru Ken SHIRATORI , Robert David KISS , Hardayal PRASHAD , Raquel IVERSON , Justin BOURRET , Michael KIM , Salim CHARANIYA
CPC分类号： C12N1/36 , C12N7/00 , C12N2750/14061 , C12N2760/12061 , C12N2760/16061 , C12N2760/18061 , C12N2760/20061 , C12N2770/16061 , C12N2770/32061 , C12N2770/36061
摘要： The invention provides for methods of viral inactivation using high temperature short time (HTST) treatment and adjustment of various parameters such that generation of precipitate and depositions of precipitate are reduced and/or minimized.
-
公开(公告)号：US20100209454A1
公开(公告)日：2010-08-19
申请号：US12594173
申请日：2008-03-31
申请人： Eckard Wimmer , Steve Skiena , Steffen Mueller , Bruce Futcher , Dimitris Papamichail , John Robert Coleman , Jeronimo Cello
发明人： Eckard Wimmer , Steve Skiena , Steffen Mueller , Bruce Futcher , Dimitris Papamichail , John Robert Coleman , Jeronimo Cello
CPC分类号： C12N7/00 , A61K39/13 , A61K39/145 , A61K2039/5254 , C07K14/005 , C12N2720/12361 , C12N2740/15061 , C12N2760/16061 , C12N2760/16121 , C12N2760/16134 , C12N2760/16162 , C12N2770/20061 , C12N2770/24161 , C12N2770/32061 , C12N2770/32621 , C12N2770/32634 , C12N2770/32661 , C12N2770/32662 , C12N2770/32671 , C12N2770/32721 , C12N2770/32761 , C12N2770/32762 , Y02A50/386 , Y02A50/388 , Y02A50/466
摘要： This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the instant attenuated virus. Further, this invention further provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of a vaccine composition comprising the instant attenuated virus.
摘要翻译： 本发明提供了一种减毒病毒，其包含经修饰的病毒基因组，其含有在基因组中多个位置工程改造的核苷酸取代，其中所述取代引入同义脱酮密码子进入基因组。 本发明的减毒病毒可用于疫苗组合物中以在受试者中诱导保护性免疫应答。 本发明还提供了合成即时减毒病毒的方法。 此外，本发明进一步提供了一种防止受试者患有病毒相关疾病的方法，包括向受试者施用预防有效剂量的包含即时减毒病毒的疫苗组合物。
-
公开(公告)号：US20170159010A1
公开(公告)日：2017-06-08
申请号：US15290986
申请日：2016-10-11
申请人： Genentech, Inc.
发明人： Masaru Ken SHIRATORI , Robert David KISS , Hardayal PRASHAD , Raquel IVERSON , Justin BOURRET , Michael KIM , Salim CHARANIYA
CPC分类号： C12N1/36 , C12N7/00 , C12N2750/14061 , C12N2760/12061 , C12N2760/16061 , C12N2760/18061 , C12N2760/20061 , C12N2770/16061 , C12N2770/32061 , C12N2770/36061
摘要： The invention provides for methods of viral inactivation using high temperature short time (HTST) treatment and adjustment of various parameters such that generation of precipitate and depositions of precipitate are reduced and/or minimized.
-
公开(公告)号：US20170067030A1
公开(公告)日：2017-03-09
申请号：US15258584
申请日：2016-09-07
发明人： Eckard Wimmer , Steve Skiena , Steffen Mueller , Bruce Futcher , Dimitris Papamichail , John Robert Coleman , Jeronimo Cello
IPC分类号： C12N7/00 , A61K39/13 , A61K39/145 , C07K14/005
CPC分类号： C12N7/00 , A61K39/13 , A61K39/145 , A61K2039/5254 , C07K14/005 , C12N2720/12361 , C12N2740/15061 , C12N2760/16061 , C12N2760/16121 , C12N2760/16134 , C12N2760/16162 , C12N2770/20061 , C12N2770/24161 , C12N2770/32061 , C12N2770/32621 , C12N2770/32634 , C12N2770/32661 , C12N2770/32662 , C12N2770/32671 , C12N2770/32721 , C12N2770/32761 , C12N2770/32762 , Y02A50/386 , Y02A50/388 , Y02A50/466
摘要： This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the instant attenuated virus. Further, this invention further provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of a vaccine composition comprising the instant attenuated virus.
摘要翻译： 本发明提供了一种减毒病毒，其包含经修饰的病毒基因组，其含有在基因组中多个位置工程改造的核苷酸取代，其中所述取代引入同义脱酮密码子进入基因组。 本发明的减毒病毒可用于疫苗组合物中以在受试者中诱导保护性免疫应答。 本发明还提供了合成即时减毒病毒的方法。 此外，本发明进一步提供了一种防止受试者患有病毒相关疾病的方法，包括向受试者施用预防有效剂量的包含即时减毒病毒的疫苗组合物。
-
公开(公告)号：US09493744B2
公开(公告)日：2016-11-15
申请号：US13844051
申请日：2013-03-15
申请人： Genentech, Inc.
发明人： Masaru Ken Shiratori , Robert David Kiss , Hardayal Prashad , Raquel Iverson , Justin Bourret , Michael Kim , Salim Charaniya
CPC分类号： C12N1/36 , C12N7/00 , C12N2750/14061 , C12N2760/12061 , C12N2760/16061 , C12N2760/18061 , C12N2760/20061 , C12N2770/16061 , C12N2770/32061 , C12N2770/36061
摘要： The invention provides for methods of viral inactivation using high temperature short time (HTST) treatment and adjustment of various parameters such that generation of precipitate and depositions of precipitate are reduced and/or minimized.
摘要翻译： 本发明提供使用高温短时间（HTST）处理和调整各种参数的病毒灭活方法，使得沉淀物的产生和沉淀的沉积减少和/或最小化。
-
10.发明授权Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof 有权能够中和流感病毒H5N1的人结合分子及其用途公开(公告)号：US08691223B2
公开(公告)日：2014-04-08
申请号：US13315475
申请日：2011-12-09
IPC分类号： A61K39/395 , A61K39/42 , C12N7/00
CPC分类号： C07K16/1018 , A61K2039/505 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C12N2760/00011 , C12N2760/00061 , C12N2760/16011 , C12N2760/16061 , C12N2760/16111 , G01N33/56983 , G01N2333/11 , G01N2469/10
摘要： Described are binding molecules such as human monoclonal antibodies that bind to influenza virus H5N1 and have neutralizing activity against influenza virus H5N1. Also described are nucleic acid molecules encoding the antibodies, and compositions comprising the antibodies and methods of identifying or producing the antibodies. The antibodies can be used in the diagnosis, prophylaxis, and/or treatment of an influenza virus H5N1 infection. In certain embodiments, the antibodies provide cross-subtype protection in vivo, such that infections with H5, H2, H6, H9, and H1-based influenza subtypes can be prevented and/or treated.
摘要翻译： 描述了结合分子，例如结合流感病毒H5N1的人单克隆抗体，并具有针对流感病毒H5N1的中和活性。 还描述了编码抗体的核酸分子和包含抗体的组合物以及鉴定或产生抗体的方法。 抗体可用于诊断，预防和/或治疗流感病毒H5N1感染。 在某些实施方案中，抗体在体内提供跨亚型保护，使得可以预防和/或治疗H5，H2，H6，H9和H1基于流感亚型的感染。
-
-
-
-
-
-
-
-
-
搜索结果
36 条记录 (耗时 0.018 秒)
